Literature DB >> 6446880

Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycin.

R N Jones, P C Fuchs, H M Sommers, T L Gavan, A L Barry, E H Gerlach.   

Abstract

Moxalactam (LY127935) exhibited greater in vitro activity than cefamandole and tobramycin against clinical isolates of Enterobacteriaceae, Aeromonas hydrophila, and Pseudomonas maltophilia. The activities of the three drugs against other microorganisms were as follows: for staphylococci, cefamandole = tobramycin greater than moxalactam; for streptococci, cefamandole greater than moxalactam greater than tobramycin; and for Pseudomonas aeruginosa, tobramycin greater than moxalactam greater than cefamandole. Moxalactam also demonstrated significant activity against the Bacteroides fragilis group and other anaerobes. Moxalactam was comparable to cefotaxime (HR756) in its inhibition of cephalothin-resistant and aminoglycoside-resistant clinical isolates.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6446880      PMCID： PMC283866          DOI： 10.1128/AAC.17.4.750

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  Cefuroxime, an in vitro Comparison with Six Other Cephalosporins.

Authors:  A L Barry; C Thornsberry; R N Jones; P C Fuchs; T L Gavan; E H Gerlach
Journal:  Proc R Soc Med       Date:  1977

2.  Piperacillin and carbenicillin; a collaborative in vitro comparison against 10,838 clinical bacterial isolates.

Authors:  R N Jones; P C Fuchs; E H Gerlach; T L Gavan
Journal:  Cleve Clin Q       Date:  1979

3.  Susceptibility of Enterobacter to cefamandole: evidence for a high mutation rate to resistance.

Authors:  C M Findell; J C Sherris
Journal:  Antimicrob Agents Chemother       Date:  1976-06       Impact factor: 5.191

4.  HR 756, the syn isomer of a new methoxyimino cephalosporin with unusual antibacterial activity.

Authors:  Y A Chabbert; A J Lutz
Journal:  Antimicrob Agents Chemother       Date:  1978-11       Impact factor: 5.191

5.  Antibacterial activity of a new 1-oxa cephalosporin compared with that of other beta-lactam compounds.

Authors:  H C Neu; N Aswapokee; K P Fu; P Aswapokee
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

6.  Comparative activity and beta-lactamase stability of cefoperazone, a piperazine cephalosporin.

Authors:  H C Neu; K P Fu; N Aswapokee; P Aswapokee; K Kung
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

7.  The comparative beta-lactamase resistance and inhibitory activity of 1-oxa cephalosporin, cefoxitin and cefotaxime.

Authors:  K P Fu; H C Neu
Journal:  J Antibiot (Tokyo)       Date:  1979-09       Impact factor: 2.649

8.  Fortimicin A: collaborative in vitro susceptibility. Comparison with amikacin and gentamicin against 11,840 clinical bacterial isolates.

Authors:  R N Jones; A L Barry; P C Fuchs; T L Gavan; H M Sommers; E H Gerlach
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

9.  Cefoperazone (T-1551), a new semisynthetic cephalosporin: comparison with cephalothin and gentamicin.

Authors:  R N Jones; P C Fuchs; A L Barry; T L Gavan; H M Sommers; E H Gerlach
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

10.  In vitro activity of LY127935.

Authors:  M Barza; F P Tally; N V Jacobus; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191
View more
  22 in total

Review 1.  Bacterial antibiotic resistance before and after clinical application in the United States.

Authors:  A L Barry; R N Jones
Journal:  Bull N Y Acad Med       Date:  1987-04

2.  A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy.

Authors:  S Vartivarian; E Anaissie; G Bodey; H Sprigg; K Rolston
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

Review 3.  The antimicrobial activity of cefotaxime: comparative multinational hospital isolate surveys covering 15 years.

Authors:  R N Jones
Journal:  Infection       Date:  1994       Impact factor: 3.553

4.  Establishment of MICs of moxalactam for control and reference anaerobic organisms in agar dilution and microdilution techniques.

Authors:  V L Sutter; J Emmerman; E Randall; R J Zabransky; R J Birk
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

5.  Susceptibilities of 45 clinical isolates of Proteus penneri.

Authors:  M Fuksa; S Krajden; A Lee
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

6.  Studies on lamoxactam penetration into the aqueous humor of the human eye.

Authors:  K F Manthey; U Ullmann
Journal:  Infection       Date:  1983 Jul-Aug       Impact factor: 3.553

7.  Comparative in vitro activities of cefpiramide and apalcillin against anaerobic bacteria.

Authors:  H Wexler; W T Carter; B Harris; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

8.  Antimicrobial activity of amikacin combinations against Enterobacteriaceae moderately susceptible to third-generation cephalosporins.

Authors:  R N Jones; R R Packer
Journal:  Antimicrob Agents Chemother       Date:  1982-12       Impact factor: 5.191

9.  Sensitivity of 341 non-fermentative gram-negative bacteria to seven beta-lactam antibiotics.

Authors:  P C Appelbaum; J Tamim; J Stavitz; R C Aber; G A Pankuch
Journal:  Eur J Clin Microbiol       Date:  1982-06       Impact factor: 3.267

10.  Tentative interpretive standards for disk susceptibility tests with moxalactam (LY127935).

Authors:  A L Barry; C Thornsberry; R N Jones; E H Gerlach
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.